Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the Potential of Eryaspase (GRASPA) as a Second-Line Treatment in Combination with Chemotherapy for Metastatic Pancreatic Cancer

Ticker(s): ERYP.PA, HALO

Who's the expert?

Name: Dr Safi Shahda - MD

Institution: Indiana University

  • GI Oncologist whose clinical practice and research focuses on pancreatic cancer.
  • PI for several investigator-initiated and other forms (cooperative, pharma trials) and is familiar with the PHASE 2B study of Eryaspace presented at ESMO.
  • Actively treats over 20 patients with metastatic pancreatic and over a dozen of localized and locally advanced patients.

Interview Questions
Q1.

How many patients do you currently treat with metastatic pancreatic cancer?

Added By: joe_mccann
Q2.

What is your view of the Eryaspase (Graspa) approach using L-asparaginase encapsulated in red blood cells to target pancreatic cancer?

Added By: joe_mccann
Q3.

On a scale of 1-10, how excited are you for Eryaspase in this indication for your patients?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.